๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome

โœ Scribed by Pang-Yen Liu; Pei-Chuan Wu; Chun-Yen Chen; Yi-Chyan Chen


Book ID
113635872
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
113 KB
Volume
33
Category
Article
ISSN
0163-8343

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Rhabdomyolysis without neuroleptic malig
โœ Norio Yasui; Tsuyoshi Kondo; Koichi Otani; Sunao Kaneko ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 65 KB

This is the ยฎrst case report of rhabdomyolysis without neuroleptic malignant syndrome induced by additional treatment of risperidone. The manifestations of this side eect were symptoms of myalgia, muscle weakness and redcoloured urine with ยฎndings of markedly elevated levels of creatine kinase and m

Neuroleptic malignant syndrome associate
โœ Heidi Lee; James Ryan; George Mullett; Brian A. Lawlor ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 248 KB

Neuroleptic malignant syndrome (NMS) is a rare and sometimes fatal adverse reaction to neuroleptic drugs. Atypical antipsychotic agents, such as risperidone, are thought to be less likely to cause N M S because of their phamacologiical profile. This is a case report of NMS associated with risperidon

Successful use of risperidone after neur
โœ Ashok N. Singh; David M. Hambidge ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 69 KB

Successful use of risperidone after neuroleptic malignant syndrome (NMS): a 1-year follow-up Neuroleptic malignant syndrome (NMS) is a rare and an acute life-threatening reaction that can occur in patients on neuroleptic medication. Few authors have addressed the issue of re-challenge in previous NM